€31.58 - That's What Analysts Think Exosens (EPA:EXENS) Is Worth After These Results

The investors in Exosens's (EPA:EXENS) will be rubbing their hands together with glee today, after the share price leapt 36% to €33.31 in the week following its full-year results. It was an okay report, and revenues came in at €394m, approximately in line with analyst estimates leading up to the results announcement. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Exosens after the latest results.

Check out our latest analysis for Exosens

Taking into account the latest results, the current consensus from Exosens' six analysts is for revenues of €466.3m in 2025. This would reflect a meaningful 18% increase on its revenue over the past 12 months. In the lead-up to this report, the analysts had been modelling revenues of €463.0m and earnings per share (EPS) of €1.50 in 2025. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

Additionally, the consensus price target for Exosens rose 8.6% to €31.58, showing a clear increase in optimism from the the analysts involved. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Exosens at €39.00 per share, while the most bearish prices it at €27.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Exosens' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Exosens' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 18% growth on an annualised basis. This is compared to a historical growth rate of 27% over the past three years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 9.6% annually. Even after the forecast slowdown in growth, it seems obvious that Exosens is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

We have estimates for Exosens from its six analysts out to 2027, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Exosens , and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.